BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 30629619)

  • 1. Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis.
    Rajasingham R; Meya DB; Greene GS; Jordan A; Nakawuka M; Chiller TM; Boulware DR; Larson BA
    PLoS One; 2019; 14(1):e0210105. PubMed ID: 30629619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda.
    Ramachandran A; Manabe Y; Rajasingham R; Shah M
    BMC Infect Dis; 2017 Mar; 17(1):225. PubMed ID: 28335769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.
    Meya DB; Manabe YC; Castelnuovo B; Cook BA; Elbireer AM; Kambugu A; Kamya MR; Bohjanen PR; Boulware DR
    Clin Infect Dis; 2010 Aug; 51(4):448-55. PubMed ID: 20597693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis.
    Li Y; Huang X; Chen H; Qin Y; Hou J; Li A; Wu H; Yan X; Chen Y
    BMC Infect Dis; 2020 Jun; 20(1):410. PubMed ID: 32532212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda.
    Nalintya E; Meya DB; Lofgren S; Huppler Hullsiek K; Boulware DR; Rajasingham R
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):231-238. PubMed ID: 29509588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100-200 cells/mm
    Wykowski J; Galagan SR; Govere S; Wallis CL; Moosa MY; Celum C; Drain PK
    BMC Infect Dis; 2020 Jan; 20(1):61. PubMed ID: 31959112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening HIV-Infected Patients with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa.
    Larson BA; Rockers PC; Bonawitz R; Sriruttan C; Glencross DK; Cassim N; Coetzee LM; Greene GS; Chiller TM; Vallabhaneni S; Long L; van Rensburg C; Govender NP
    PLoS One; 2016; 11(7):e0158986. PubMed ID: 27390864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of single-dose AmBisome pre-emptive treatment for the prevention of cryptococcal meningitis in African low and middle-income countries.
    Rajasingham R; Nalintya E; Israelski DM; Meya DB; Larson BA; Boulware DR
    Med Mycol; 2022 Feb; 60(2):. PubMed ID: 35026017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryptococcal Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing.
    Rajasingham R; Wake RM; Beyene T; Katende A; Letang E; Boulware DR
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30257903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay.
    Rugemalila J; Maro VP; Kapanda G; Ndaro AJ; Jarvis JN
    Trop Med Int Health; 2013 Sep; 18(9):1075-1079. PubMed ID: 23937699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A qualitative evaluation of an implementation study for cryptococcal antigen screening and treatment in Uganda.
    Lofgren SM; Nalintya E; Meya DB; Boulware DR; Rajasingham R
    Medicine (Baltimore); 2018 Aug; 97(31):e11722. PubMed ID: 30075580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012.
    McKenney J; Bauman S; Neary B; Detels R; French A; Margolick J; Doherty B; Klausner JD
    Clin Infect Dis; 2015 Mar; 60(6):959-65. PubMed ID: 25422390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, Brazil.
    Vidal JE; Toniolo C; Paulino A; Colombo A; Dos Anjos Martins M; da Silva Meira C; Pereira-Chioccola VL; Figueiredo-Mello C; Barros T; Duarte J; Fonseca F; Alves Cunha M; Mendes C; Ribero T; Dos Santos Lazera M; Rajasingham R; Boulware DR
    Trop Med Int Health; 2016 Dec; 21(12):1539-1544. PubMed ID: 27699970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program--Vietnam.
    Smith RM; Nguyen TA; Ha HT; Thang PH; Thuy C; Lien TX; Bui HT; Le TH; Struminger B; McConnell MS; Fanfair RN; Park BJ; Harris JR
    PLoS One; 2013; 8(4):e62213. PubMed ID: 23626792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania.
    Faini D; Kalinjuma AV; Katende A; Mbwaji G; Mnzava D; Nyuri A; Glass TR; Furrer H; Hatz C; Boulware DR; Letang E
    J Acquir Immune Defic Syndr; 2019 Feb; 80(2):205-213. PubMed ID: 30422904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation.
    Jarvis JN; Govender N; Chiller T; Park BJ; Longley N; Meintjes G; Bekker LG; Wood R; Lawn SD; Harrison TS
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(6):374-9. PubMed ID: 23015379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LATERAL FLOW ASSAY FOR CRYPTOCOCCAL ANTIGEN: AN IMPORTANT ADVANCE TO IMPROVE THE CONTINUUM OF HIV CARE AND REDUCE CRYPTOCOCCAL MENINGITIS-RELATED MORTALITY.
    Vidal JE; Boulware DR
    Rev Inst Med Trop Sao Paulo; 2015 Sep; 57 Suppl 19(Suppl 19):38-45. PubMed ID: 26465368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study.
    Lakoh S; Rickman H; Sesay M; Kenneh S; Burke R; Baldeh M; Jiba DF; Tejan YS; Boyle S; Koroma C; Deen GF; Beynon F
    BMC Infect Dis; 2020 Feb; 20(1):141. PubMed ID: 32059703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory Reflex and Clinic-Based Point-of-Care Cryptococcal Antigen Screening for Preventing Meningitis and Mortality Among People Living With HIV.
    Drain PK; Galagan SR; Govere S; Krows M; Thulare H; Wallis CL; Gosnell BI; Moosa MY; Celum C; Bassett IV
    J Acquir Immune Defic Syndr; 2021 Aug; 87(5):1205-1213. PubMed ID: 33990495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study.
    Longley N; Jarvis JN; Meintjes G; Boulle A; Cross A; Kelly N; Govender NP; Bekker LG; Wood R; Harrison TS
    Clin Infect Dis; 2016 Mar; 62(5):581-587. PubMed ID: 26565007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.